FDA issued a Warning Letter to BioReliance Corporation on 1/5/2009 for a later inspection.
483 BioReliance Jun 2001

483 BioReliance Jun 2001

Barbara Holladay FDA, Christine Smith FDA$595.00 - Available Now

FDA investigators audited the BioReliance - Rockville, MD, United States facility and issued inspectional observations (via FDA 483) on 22 Jun 2001.

Product details

  • Category: Human Drugs
  • Inspection end: 22 Jun 2001
  • Location: Rockville, United States
  • FEI: 1122041
Add To Cart